Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development-Reference-Cited by-同舟云学术

Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development

Published:2012-02 Issue:1 Volume:13 Page:1-10
ISSN:1528-4336
Container-title:HIV Clinical Trials
language:en
Short-container-title:HIV Clinical Trials

Author:

Morris Bethany L.,Scott Callie A.,Wilkin Timothy J.,Sax Paul E.,Gulick Roy M.,Freedberg Kenneth A.,Schackman Bruce R.

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

http://www.tandfonline.com/doi/pdf/10.1310/hct1301-1

Reference35 articles.

1. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies

2. Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

3. Clinical Outcome of HIV-Infected Patients with Discordant Virological and Immunological Response to Antiretroviral Therapy

4. Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost–effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice;Pharmacogenomics;2015-12

2. The Lifetime Medical Cost Savings From Preventing HIV in the United States;Medical Care;2015-04

3. Performance of a Mathematical Model to Forecast Lives Saved from HIV Treatment Expansion in Resource-Limited Settings;Medical Decision Making;2014-10-20